Organon & Co. Hits New 52-Week High at USD 13.38

Organon & Co., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 13.38 on April 28, 2026. This achievement marks a notable recovery from its 52-week low of USD 5.69, reflecting a substantial increase in its stock price over the past year. Despite this recent uptick, Organon & Co. has experienced a challenging year, with its stock performance down by 35.68% compared to the S&P 500, which has gained 29.12% during the same period. The company's market capitalization stands at USD 1,650 million, and it currently has a price-to-earnings (P/E) ratio of 3.00, indicating a low valuation relative to its earnings. Additionally, Organon & Co. offers a dividend yield of 0.94%, although its return on equity remains at 0.00%. The company's debt-to-equity ratio is reported at 8,066.00, highlighting its financial structure. As it continues to navigate the competitive landscape of the pharmaceuticals industry, this new high could be a pivotal moment for the company.